For Cerus's INTERCEPT plasma system, how can we optimize the trade-off between reducing pathogen inactivation time and maintaining plasma protein quality?

Introduction

The trade-off between reducing pathogen inactivation time and maintaining plasma protein quality for Cerus's INTERCEPT plasma system presents a critical challenge. This scenario involves balancing the efficiency of pathogen elimination with the preservation of essential plasma components. I'll analyze this trade-off by examining the product, stakeholders, metrics, and potential experiments to inform a strategic recommendation.

Step 1

Clarifying Questions (3 minutes)

• Based on the regulatory landscape, I'm thinking there might be specific FDA requirements for pathogen inactivation efficacy. Could you clarify the current regulatory standards we need to meet?

Why it matters: Ensures our solution complies with legal requirements Expected answer: Specific log reduction targets for various pathogens Impact on approach: Would set a minimum threshold for inactivation time

• Considering the competitive landscape, I'm assuming cost is a factor for hospitals. How price-sensitive is our target market for plasma treatment systems?

Why it matters: Helps balance performance improvements with cost implications Expected answer: Moderate price sensitivity, with focus on total cost of ownership Impact on approach: Would influence the trade-off between advanced technology and affordability

• Looking at user needs, I'm thinking about the workflow in blood banks. How critical is processing time for their operations?

Why it matters: Determines the importance of reducing inactivation time Expected answer: Significant impact on throughput and staff utilization Impact on approach: Would prioritize time reduction if it's a major pain point

• From a technical perspective, I'm curious about the current inactivation method. What technology are we using, and are there known limitations?

Why it matters: Identifies potential areas for innovation or optimization Expected answer: UV light-based system with some protein degradation issues Impact on approach: Would focus on refining existing tech or exploring new methods

• Regarding our development resources, I'm wondering about our R&D capabilities. What's our current team composition and budget for this project?

Why it matters: Determines the scope and timeline of potential solutions Expected answer: Dedicated team with expertise in biochemistry and engineering Impact on approach: Would tailor the complexity of solutions to match our resources